title: In vitro activity of daptomycin against Staphylococci isolated from bacteremia and community-onset skin and soft tissue infections in France: data from two nationwide studies.
abstract: Staphylococci are a leading cause of skin and soft tissue infections (SSTIs) and bacteremia in France, a country with a high prevalence of oxacillin resistance. We evaluated the in vitro activity of daptomycin compared with reference compounds against 445 Staphylococcus aureus and 53 coagulase-negative Staphylococci (CNS) collected during two large nationwide studies performed in 2006 and 2007. The percentage of oxacillin resistance among S. aureus was 13.6% (SSTIs) and 30.7% (bacteremia). Daptomycin showed lower MIC(90) levels compared to vancomycin, teicoplanin, and linezolid (0.19 mg/L vs. 2, 1.5, and 1 mg/L, respectively), irrespective of oxacillin susceptibility. Amongst the CNS, 64.2% of the isolates originated from clinical bacteremia were resistant to oxacillin and 24.5% to teicoplanin; all but one Staphylococci were susceptible to daptomycin (MIC = 1.5 mg/l). As with linezolid, daptomycin seems to constitute an alternative option to treat some staphylococcal infections in the French context of high oxacillin resistance prevalence and high glycopeptides MIC.
authors.affiliation: Department of Biology and Infection Control, Centre Hospitalier de Dourdan, 91415, Dourdan, France.
authors.forename: O
authors.initials: O
authors.lastname: Gallon
authors.forename: C
authors.initials: C
authors.lastname: Guillet-Caruba
authors.forename: B
authors.initials: B
authors.lastname: Lamy
authors.forename: F
authors.initials: F
authors.lastname: Laurent
authors.forename: F
authors.initials: F
authors.lastname: Doucet-Populaire
authors.forename: J-W
authors.initials: JW
authors.lastname: Decousser
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D016470:Bacteremia / Q000188:drug therapy* / Q000382:microbiology; D003030:Coagulase / Q000378:metabolism; D015169:Colony Count, Microbial; D017714:Community-Acquired Infections / Q000188:drug therapy / Q000382:microbiology; D017576:Daptomycin / Q000494:pharmacology / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D024881:Drug Resistance, Bacterial; D005602:France; D006801:Humans; D008826:Microbial Sensitivity Tests; D010068:Oxacillin / Q000494:pharmacology / Q000627:therapeutic use; D018461:Soft Tissue Infections / Q000188:drug therapy* / Q000382:microbiology; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000382:microbiology; D013207:Staphylococcal Skin Infections / Q000188:drug therapy* / Q000382:microbiology; D013210:Staphylococcus / Q000187:drug effects / Q000201:enzymology; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D003030:Coagulase; D017576:Daptomycin; D010068:Oxacillin